Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Fresenius SE & Co. KGaA (OTC: FSNUY).

Full DD Report for FSNUY

You must become a subscriber to view this report.


Recent News from (OTC: FSNUY)

Fresenius' (FSNUY) CEO Stephan Sturm on Q1 2018 Results - Earnings Call Transcript
Fresenius SE & Co. KGaA ADR (FSNUY) Q1 2018 Earnings Conference Call May 3, 2018, 08:00 AM ET Executives Stephan Sturm - CEO Rachel Empey - CFO Markus Georgi - SVP IR Analysts Michael Jungling - Morgan Stanley Veronika Dubajova - Goldman Sachs Ian Douglas-Pennant - ...
Source: SeekingAlpha
Date: May, 06 2018 09:06
Fresenius SE & Co. KGaA ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Fresenius SE & Co. KGaA ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 13:29
Fresenius SE & Co reports Q1 results
Fresenius SE & Co ( OTCQX:FSNUY ): Q1 EPS of €0.81 More news on: Fresenius SE & Co. KGaA ADR, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: May, 03 2018 06:25
5 German Dividend Growth Stocks (Part II)
Recap: 3 takeaways of universal importance In part I of “ 5 German Dividend Growth Stocks ,“ I gave a short introduction into the German stock market including differences regarding dividend policy. First takeaway: Finding German dividend growth stocks is pain, but it's possi...
Source: SeekingAlpha
Date: March, 08 2018 15:41
Akorn Craters 32% On FDA Probe - Time To Buy?
Investors in Akorn Inc. (NSDQ: AKRX ) got a nasty wake up call this morning as Fresenius SE & Co. KGaA ( FSNUY ) raised doubts about its acquisition of Akorn amid an FDA probe into alleged allegations of FDA integrity requirements relating to product developments. Was the 32% sell-off i...
Source: SeekingAlpha
Date: February, 27 2018 16:42
Fresenius SE & Co. KGaA ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Fresenius SE & Co. KGaA ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: February, 27 2018 12:11
Fresenius' (FSNUY) CEO Stephan Sturm on Q4 2017 Results - Earnings Call Transcript
Fresenius (FSNUY) Q4 2017 Earnings Conference Call February 27, 2018 08:00 AM ET Executives Markus Georgi - IR Stephan Sturm - CEO Rachel Empey - CFO Analysts Lisa Clive - Bernstein Michael Jüngling - Morgan Stanley Tom Jones - Berenberg Hassan Al-Wakeel - Barcla...
Source: SeekingAlpha
Date: February, 27 2018 12:07
Fresenius reports 14th consecutive record year, aims at strong growth in 2018 and confirms mid-term growth targets
Fresenius reports 14th consecutive record year, aims at strong growth in 2018 and confirms mid-term growth targets
Source: OTC Markets
Date: February, 27 2018 00:00
Fresenius SE: A High Quality Healthcare Company Unfairly Punished By The Market
In June 2017, Fresenius SE ( OTCQX:FSNUF ) stock price was trading close to € 80 before collapsing to € 60. The sell-off can be explained by a combination of events: - A deterioration of the pricing environment for generics. - A record number of generics approved by the FDA...
Source: SeekingAlpha
Date: February, 12 2018 14:20
Fresenius: Proven Value Creation Amidst M&A Doubts
Shares of Fresenius SE (FSNUF) (FSNUY) have basically been flat over the past 52 weeks, with the stock bouncing between $18 and $22 after a steady climb over the past decade. Management has come into question after the controversial proposed acquisition of Akorn (AKRX) that was announced amids...
Source: SeekingAlpha
Date: January, 20 2018 02:38

 


About Fresenius SE & Co. KGaA (OTC: FSNUY)

Logo for Fresenius SE & Co. KGaA (OTC: FSNUY)

Fresenius is a global health care group providing products and services for dialysis, hospitals, and outpatient medical care. In addition, Fresenius focuses on hospital operation. We also manage projects and provide services for hospitals and other health care facilities. In , Group sales were EUR . billion.

 

 

 

Current Management

  • Stephan Sturm / CEO
  • Rachel Empey / CFO
  • Rice Powell /

Current Share Structure

  • Market Cap: $45,136,405,724 - 03/09/2018
  • Authorized: 669,161,917 - 06/30/2017
  • Issue and Outstanding: 554,773,915 - 01/31/2018

 


Recent Filings from (OTC: FSNUY)

Supplemental Information - Fresenius Factsheet FY/2017
Filing Type: Supplemental Information - Fresenius Factsheet FY/2017Filing Source: OTC Markets
Filing Date: March, 01 2018
Supplemental Information - Fresenius CC Q4 and FY/17 Transcript
Filing Type: Supplemental Information - Fresenius CC Q4 and FY/17 TranscriptFiling Source: OTC Markets
Filing Date: March, 01 2018
Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions by persons discharging managerial
Filing Type: Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions bFiling Source: OTC Markets
Filing Date: January, 05 2018
Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Filing Type: Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions bFiling Source: OTC Markets
Filing Date: December, 29 2017
Notice of Change in Substantial Holder Interest - Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution / Allianz Global Investors GmbH
Filing Type: Notice of Change in Substantial Holder Interest - Release according to Article 26, Section 1 of the Filing Source: OTC Markets
Filing Date: December, 11 2017
Quarterly Report - 1st -3rd quarter and 3rd quarter 2017 (IFRS)
Filing Type: Quarterly Report - 1st -3rd quarter and 3rd quarter 2017 (IFRS)Filing Source: OTC Markets
Filing Date: November, 03 2017
Supplemental Information - Fresenius Q3/17 Factsheet
Filing Type: Supplemental Information - Fresenius Q3/17 FactsheetFiling Source: OTC Markets
Filing Date: November, 03 2017
Supplemental Information - Fresenius CC 3rd quarter 2017 transcript
Filing Type: Supplemental Information - Fresenius CC 3rd quarter 2017 transcriptFiling Source: OTC Markets
Filing Date: November, 03 2017
Notice of Change in Substantial Holder Interest - Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution / Allianz Global Investors
Filing Type: Notice of Change in Substantial Holder Interest - Release according to Article 26, Section 1 of the Filing Source: OTC Markets
Filing Date: November, 03 2017
Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Filing Type: Officer/Director/Affiliate Stock Transactions - Notification and public disclosure of transactions bFiling Source: OTC Markets
Filing Date: September, 05 2017

 

 


Daily Technical Chart for (OTC: FSNUY)

Daily Technical Chart for (OTC: FSNUY)


Stay tuned for daily updates and more on (OTC: FSNUY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: FSNUY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FSNUY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of FSNUY and does not buy, sell, or trade any shares of FSNUY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/